Cargando…
Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders
Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV in...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557643/ https://www.ncbi.nlm.nih.gov/pubmed/33045856 http://dx.doi.org/10.1177/2058738420961202 |
_version_ | 1783594466630696960 |
---|---|
author | Lotfi, Abeya A Mohamed, Asmaa E Shalaby, Nahela A Eissa, Deena S El-Dabaa, Ehab Sallam, Ayman M Kamel, Mahmoud M Abdelaziz, Hisham El-Afifi, Amal M Abdel-Moneim, Ahmed S |
author_facet | Lotfi, Abeya A Mohamed, Asmaa E Shalaby, Nahela A Eissa, Deena S El-Dabaa, Ehab Sallam, Ayman M Kamel, Mahmoud M Abdelaziz, Hisham El-Afifi, Amal M Abdel-Moneim, Ahmed S |
author_sort | Lotfi, Abeya A |
collection | PubMed |
description | Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection. |
format | Online Article Text |
id | pubmed-7557643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-75576432020-10-26 Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders Lotfi, Abeya A Mohamed, Asmaa E Shalaby, Nahela A Eissa, Deena S El-Dabaa, Ehab Sallam, Ayman M Kamel, Mahmoud M Abdelaziz, Hisham El-Afifi, Amal M Abdel-Moneim, Ahmed S Int J Immunopathol Pharmacol Original Research Article Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection. SAGE Publications 2020-10-13 /pmc/articles/PMC7557643/ /pubmed/33045856 http://dx.doi.org/10.1177/2058738420961202 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Lotfi, Abeya A Mohamed, Asmaa E Shalaby, Nahela A Eissa, Deena S El-Dabaa, Ehab Sallam, Ayman M Kamel, Mahmoud M Abdelaziz, Hisham El-Afifi, Amal M Abdel-Moneim, Ahmed S Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders |
title | Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders |
title_full | Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders |
title_fullStr | Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders |
title_full_unstemmed | Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders |
title_short | Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders |
title_sort | occult hepatitis c virus infection in patients with malignant lymphoproliferative disorders |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557643/ https://www.ncbi.nlm.nih.gov/pubmed/33045856 http://dx.doi.org/10.1177/2058738420961202 |
work_keys_str_mv | AT lotfiabeyaa occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT mohamedasmaae occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT shalabynahelaa occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT eissadeenas occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT eldabaaehab occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT sallamaymanm occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT kamelmahmoudm occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT abdelazizhisham occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT elafifiamalm occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders AT abdelmoneimahmeds occulthepatitiscvirusinfectioninpatientswithmalignantlymphoproliferativedisorders |